NICE Final guidance: Myelofibrosis – ruxolitinib (review of TA289) [831]
We are happy to share with everyone a very positive outcome from the NICE review of ruxolitinib. Particular thanks to everyone who responded to information requests, our patient attendees, patient advocacy teams and clinical experts. What has NICE said? Ruxolitinib (Jakavi) is recommended as a possible treatment for treating disease-related splenomegaly or symptoms in adults…